FHA
XLRN

Flagship Harbor Advisors’s Acceleron Pharma XLRN Stock Holding History

Flagship Harbor Advisors’s Portfolio XLRN Stock Details XLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-200
Closed -$22K – 1954
2020
Q3 		$22K Buy
+200
New +$19.9K ﹤0.01% 1116

Other funds holding XLRN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Flagship Harbor Advisors's XLRN Position: Q4 2020 in Review

Flagship Harbor Advisors sold out of Acceleron Pharma (XLRN) in Q4 2020, closing a stake of 200 shares — an estimated $22K sold.

Flagship Harbor Advisors first reported a position in XLRN in Q3 2020 and held it in 1 quarter. The position peaked at $22K in Q3 2020. 253 funds tracked by Wall St. Rank hold XLRN as of Q4 2020.

  • Flagship Harbor Advisors reported no remaining Acceleron Pharma position as of Q4 2020 after selling out during the quarter.
  • Flagship Harbor Advisors sold 200 Acceleron Pharma shares in Q4 2020, an estimated $22K.
  • Flagship Harbor Advisors first reported a position in Acceleron Pharma in Q3 2020 and held it in 1 quarter.
  • Flagship Harbor Advisors's Acceleron Pharma position peaked at $22K in Q3 2020.
  • 253 funds tracked by Wall St. Rank held Acceleron Pharma as of Q4 2020.

Based on Flagship Harbor Advisors's 13F filing for Q4 2020, filed 8 Feb 2021.